دورية أكاديمية
[Anti(lymph)angiogenic Strategies to Improve Corneal Graft Survival].
| العنوان: | [Anti(lymph)angiogenic Strategies to Improve Corneal Graft Survival]. |
|---|---|
| عنوان ترانسليتريتد: | Antihämangiogene/antilymphangiogene Strategien zur Verbesserung des Transplantatüberlebens nach Keratoplastik. |
| المؤلفون: | Bock F; Zentrum für Augenheilkunde, Labor für experimentelle Augenheilkunde, Uniklinik Köln., Cursiefen C; Zentrum für Molekulare Medizin Köln (ZMMK), Universität zu Köln. |
| المصدر: | Klinische Monatsblatter fur Augenheilkunde [Klin Monbl Augenheilkd] 2017 May; Vol. 234 (5), pp. 674-678. Date of Electronic Publication: 2017 May 15. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | German |
| بيانات الدورية: | Publisher: Thieme Country of Publication: Germany NLM ID: 0014133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-3999 (Electronic) Linking ISSN: 00232165 NLM ISO Abbreviation: Klin Monbl Augenheilkd Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Stuttgart : Thieme Original Publication: Stuttgart. |
| مواضيع طبية MeSH: | Angiogenesis Inhibitors/*administration & dosage , Corneal Transplantation/*adverse effects , Graft Rejection/*immunology , Graft Rejection/*prevention & control , Graft Survival/*drug effects , Graft Survival/*immunology , Lymphangiogenesis/*drug effects, Animals ; Disease Models, Animal ; Graft Rejection/etiology ; Immunotherapy/methods ; Lymphangiogenesis/immunology ; Treatment Outcome |
| مستخلص: | Corneal transplantation (keratoplasty) is the most frequently performed form of transplantation worldwide. A rejection reaction against the transplant is the main complication occurring after transplantation in an already vascularized, so-called "high-risk" recipient eye. Our group has shown that clinically invisible lymphatic vessels play a crucial role in the induction of a rejection reaction against the corneal graft, and that anti-(lymph)angiogenic therapies in the mouse model of keratoplasty can significantly improve transplant survival. The underlying mechanisms, which improve transplant survival through anti-lymphangiogenic therapies have not been well understood. We assume that the blockade of lymph vessel sprouting leads to a tolerance (and not to a simple ignorance) of the transplant, in which the antigen-presenting cells are held longer in the cornea and, thus, an immunomodulation of these cells occurs. Therefore, an important goal of our project is to find out whether and when transplant tolerance comes from a corneal anti-lymphangiogenic therapy. We assume that the antigen-presenting cells will have a different maturity level and that more tolerogenic effector cells (regulatory T cells, Tregs) develop in the absence of lymphatic vessels. Current anti(lymph)angiogenic therapies have the disadvantage that they are primarily effective on actively growing vessels. Most patients who receive high-risk keratoplasty often present in the clinic with already established, mature corneal blood and lymphatic vessels. At present, there are no lymph vessel regressing strategies, and the mechanisms regulating the maturation of the lymphatics are largely unknown. Therefore, our second goal is to develop new strategies for the regression of existing, pathological lymphatic vessels in the cornea. We are testing both destructive strategies, such as photodynamic therapy and diathermy as well as strategies for the molecular destabilization of the lymph vessel endothelium. Thus, our project identifies the precise mechanisms by which anti-lymphangiogenic therapies improve transplant survival, and we are developing new strategies to push back mature lymphatics in the high-risk setting. (Georg Thieme Verlag KG Stuttgart · New York.) |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) |
| تواريخ الأحداث: | Date Created: 20170516 Date Completed: 20180305 Latest Revision: 20220410 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1055/s-0043-108248 |
| PMID: | 28505675 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1439-3999 |
|---|---|
| DOI: | 10.1055/s-0043-108248 |